Organization
Department of Breast Oncology, Peking University Cancer Hospital
4 abstracts
Abstract
Retrospective analysis of factors impacting efficacy of patients with later stage breast cancer receiving neoadjuvant therapy.Org: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Beijing University Cancer Hospital, Beijing University Cancer Hospital & Institute, Department of Breast Oncology, Peking University Cancer Hospital,
Abstract
First-in-human phase 1 study of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, West China Hospital, Sichuan University, Chengdu Origen Biotechnology, China National Biotec Group,
Abstract
PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC).Org: Fudan University Shanghai Cancer Center, Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Department of Breast Oncology, Peking University Cancer Hospital, Harbin Medical University Cancer Hospital,
Abstract
A randomized controlled trial comparing primary tumor resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group study JCOG1017.Org: Okayama University Hospital, Department of Breast Oncology, Peking University Cancer Hospital, The Cancer Institute Hospital of JFCR, Tokyo, Japan, NHO Shikoku Cancer Center, Gunma Cancer Center,